cancer, associated chronic anemia
DISEASE INTERVENTION COMPARISON RESULTS
Lancet. 2009 May 2;373(9674):1532-42 Meta-Analysis
IN cancer, associated chronic anemia The Use of
erythropoietin analogs, recombinant human erythropoiesis-stimulating agents
As Treatment, Chronic
Is worse Than
placebo
To mortality (mean follow-up 6-8 months): 12% with erythropoietin VS 11% with placebo